| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Amneal Pharmaceuticals, Inc.$17.01
-0.01 (-0.06%)
C 48Pipeline Score Fair Value Generics · Commercial
Market Cap
4.04 B
EPS
0.39
P/E Ratio
33.91 $
Value Trade
15.33 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
722.52 M
R&D Expenses
38.38 M
Operating CF
-26.74 M
Total Assets
3.54 B
Total Liabilities
3.54 B
Equity
-45.41 M
D/E Ratio
12,345
2.48 %
Week
-6.41 %
1 Month
-14.93 %
3 Month
8 %
6 Month
116.38 %
5 Year
36.11 %
All Time
Cash Data
Cash Position
204.41 M
Monthly Burn
8.91 M
Runway
21 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
1.73 M
52 Week Range
7.07 - 15.42
% held by Insiders
48.82 %
% held by Institutions
47.46 %
Enterprise Value
6.62 B
Total Shares
318.70 M
Short %
4.62 %
Float Shares
169.55 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amneal Pharmaceuticals, Inc.
164Total events
2Upcoming
55Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 2
Event history 162
Jun 9, 2026
◆Oral PresentationPresentation
Amneal presentation at Goldman Sachs 47th Annual Global Healthcare Conference 2026
Jun 5, 2026
▲Interim AnalysisCREXONTApprovedTrial
Full study population interim Phase 4 ELEVATE-PD results announced
Parkinson's diseasesource ↗
Jun 5, 2026
●Oral PresentationCREXONTApprovedPresentation
Presentation at ATRMD 2026 Congress
Parkinson's diseasesource ↗
Jun 4, 2026
▲FDA ApprovalFDA Decision
FDA approval of romidepsin injection solution
cutaneous T-cell lymphomasource ↗
May 1, 2026
May 2026
▲Label ExpansionCREXONTApprovedFDA Decision
FDA approved labeling update for sprinkling administration
Parkinson's diseasesource ↗
Apr 22, 2026
Apr 20, 2026
▲Oral PresentationCREXONTApprovedPresentation
Positive interim Phase 4 ELEVATE-PD results presented at AAN 2026
Parkinson's diseasesource ↗
Apr 14, 2026
▲Product Launchalbuterol sulfate inhalation aerosolPost-Market
U.S. launch of albuterol sulfate inhalation aerosol
bronchospasm, exercise-induced bronchospasmsource ↗
Drug Pipeline Intelligence
C48
Pipeline Score $2.3B
Pipeline ValueFair Value
Valuation Signal10
Drugs Scored1.9x
rNPV / MCap Top 72%
Small Cap (rank 256 of 911)
Percentile RankAmneal Pharmaceuticals, Inc. carries a moderate pipeline score (48/100), with $3.6B risk-adjusted pipeline value, led by Phenazopyridine Tables, USP in Uncomplicated Urinary Tract Infections (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phenazopyridine Tables, USP Small molecule | Uncomplicated Urinary Tract Infections | Phase 3 | NCT01650051 | 49% | $774M | COMPLETED | 424 | - | - | Feb 1, 2014 | - | Jun 26, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CREXONT | Parkinson's disease | Phase 4 | 2026-06-05 | Good On time increase: from IR CD LD 3.33 hours, from IR CD LD COMT 3.20 hours, from RYTARY 3.03 hours; Off time reduction: from IR CD LD 3.20 hours, from IR CD LD COMT 2.96 hours, from RYTARY 2.4 hours; MDS UPDRS improvement: from IR CD LD -14.6 points, from IR CD LD COMT -9.9 points, from RYTARY -10.0 points Read More | Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT in Parkinson's Disease Read More | |
CREXONT | Parkinson's disease | Phase 4 | 2026-06-05 | Good On time increase: from IR CD LD 3.33 hours, from IR CD LD COMT 3.20 hours, from RYTARY 3.03 hours; Off time reduction: from IR CD LD 3.20 hours, from IR CD LD COMT 2.96 hours, from RYTARY 2.4 hours; MDS UPDRS improvement: from IR CD LD -14.6 points, from IR CD LD COMT -9.9 points, from RYTARY -10.0 points Read More | Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT in Parkinson's Disease Read More | |
CREXONT | Parkinson's disease | Phase 4 | 2026-06-05 | Good On time increase: from IR CD LD 3.33 hours, from IR CD LD COMT 3.20 hours, from RYTARY 3.03 hours; Off time reduction: from IR CD LD 3.20 hours, from IR CD LD COMT 2.96 hours, from RYTARY 2.4 hours; MDS UPDRS improvement: from IR CD LD -14.6 points, from IR CD LD COMT -9.9 points, from RYTARY -10.0 points Read More | Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT in Parkinson's Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AMRX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AMRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AMRX▼ -0.1%today
Amneal to Report Second Quarter 2026 Results on July 30, 2026
Amneal Pharmaceuticals, Inc. has announced it will report its second quarter 2026 financial results on July 30, 2026, before the market opens. The company will host an audio webcast at 8:30 a.m. ET for investors. Interested parties can register for the webcast through the company's Investor Relations website.
Read more →AMRXAmneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT in Parkinson's Disease
Amneal Pharmaceuticals announced positive interim results from the Phase 4 ELEVATE-PD study, showing significant benefits of CREXONT in Parkinson's disease treatment. The full study population of 214 patients reported increases in 'Good On' time and improvements in motor function after switching to CREXONT from other therapies, including RYTARY. The findings support CREXONT's efficacy and safety and will contribute to ongoing evaluations over a 12-month follow-up period.
Read more →AMRX▲ +5%on this newsshared move
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Amneal Pharmaceuticals announced that the U.S. FDA has approved its romidepsin injection solution, offering a ready-to-use formulation that eliminates the need for reconstitution. This approval grants Amneal a Competitive Generic Therapy designation, providing 180 days of market exclusivity and bolstering its injectables portfolio. The product is indicated for treating cutaneous T-cell lymphoma in adult patients who have had prior systemic therapy. While the approval highlights a significant advancement in Amneal’s product offerings, it also presents potential adverse reactions that could affect patient acceptance in the market.
Read more →AMRXAmneal to Participate in Goldman Sachs 47th Annual Global Healthcare Conference 2026
Amneal Pharmaceuticals will participate in the Goldman Sachs 47th Annual Global Healthcare Conference from June 8-10, 2026. Chirag Patel, Co-CEO, will present on June 9 at 8:40 AM EDT. This event offers Amneal an opportunity to highlight its diverse portfolio of medicines and engage with investors.
Read more →AMRXAmneal Reports First Quarter 2026 Financial Results
Amneal Pharmaceuticals reported strong financial results for the first quarter of 2026, with net revenue of $723 million, marking a 4% increase year-over-year. The company saw a notable rise in net income, up by 411%, and confirmed its increased guidance for the full year 2026. The performance was particularly driven by their Specialty business, which benefited from product launches, including CREXONT® and BREKIYA® autoinjector. Overall, Amneal's diversified portfolio appears to be generating robust growth, suggesting a positive outlook for the company.
Read more →AMRXAmneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance - Acquisition Positions Amneal to Capi
Amneal Pharmaceuticals has announced its agreement to acquire Kashiv BioSciences in a move aimed at establishing a global biosimilars leader. The deal involves $375 million in cash and equity at closing, with additional potential payments linked to regulatory milestones. Following the announcement, Amneal reported strong preliminary financial results for Q1 2026 and raised its full year guidance, indicating robust performance across its business segments. The transaction is positioned to leverage significant growth in the biosimilars sector ahead of a projected $300 billion loss-of-exclusivity wave in global biologics over the next decade.
Read more →AMRXAMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Q1 2026 Net Revenue of $723 million GAAP Net Income of $62 million Diluted Income per Share of $0.19 Adjusted EBITDA of $202 million Adjusted Diluted EPS of $0.27 No Ch
Amneal Pharmaceuticals reported a strong performance for Q1 2026, with net revenues reaching $723 million, reflecting a 4% increase from the previous year. The company's GAAP net income soared to $62 million, a notable increase of 411% year-over-year. Amneal also reaffirmed its previously announced increased guidance for the full year 2026, highlighting confidence in its growth prospects. However, the firm faced a decline in AvKARE revenues and potential risks from ongoing acquisitions. Overall, the results indicate a robust start to the year fueled by strong business drivers and product launches.
Read more →AMRXKashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
Kashiv BioSciences has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals. This merger aims to create a fully integrated global biosimilar leader, combining Kashiv's expertise in biosimilars with Amneal's commercialization capabilities. The transaction is expected to close in the second half of 2026, pending shareholder and regulatory approvals.
Read more →AMRXAmneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study, showing that patients switching to CREXONT experienced significant increases in daily 'Good On' time and reductions in 'Off' time. The study involved 111 patients and highlighted the efficacy of CREXONT across various prior treatments, including RYTARY. The findings suggest that CREXONT could enhance symptom management for Parkinson's disease patients.
Read more →AMRXAmneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
Amneal Pharmaceuticals has launched its first two metered-dose inhalation products in the U.S., namely albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol. Both products, approved by the FDA in 2025, aim to enhance patient access to respiratory treatments. The launch signifies Amneal's entry into the complex inhalation category, with further products in development.
Read more →AMRXAmneal Launches Bimatoprost Ophthalmic Solution, 0.01%
Amneal Pharmaceuticals has launched bimatoprost ophthalmic solution 0.01%, a generic equivalent of LUMIGAN, aimed at reducing intraocular pressure in glaucoma patients. This addition to their Affordable Medicines portfolio is expected to enhance access to essential treatments as glaucoma cases rise. The product's launch is anticipated to drive growth within Amneal's segment.
Read more →AMRXAmneal to Report First Quarter 2026 Results on May 1, 2026
Amneal Pharmaceuticals, Inc. will announce its first quarter 2026 financial results on May 1, 2026, before the market opens. An audio webcast is scheduled for 8:30 a.m. ET, providing investors with access to the results and a conference call. The company emphasizes its commitment to affordable and innovative medicines.
Read more →AMRXAmneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month
Amneal Pharmaceuticals has announced a $2 million donation to various patient assistance foundations in honor of Parkinson's Awareness Month. This initiative aims to support individuals living with Parkinson's disease by helping them manage out-of-pocket costs for FDA-approved medications. The company has donated a total of $3.5 million over the past two years to enhance patient care and education.
Read more →AMRXAmneal to Participate in Upcoming Investor Conference
Amneal Pharmaceuticals, Inc. has announced that Co-Chief Executive Chirag Patel will participate in the Barclays 28th Annual Global Healthcare Conference on March 10, 2026. The event will include a fireside chat at 11:00 AM EST, and Amneal plans to provide a webcast for those unable to attend the live session. This participation may enhance investor relations and visibility within the healthcare sector.
Read more →AMRXAmneal Reports Fourth Quarter and Full Year 2025 Financial Results
Amneal Pharmaceuticals reported its financial results for Q4 and the full year 2025, showing significant growth with net revenue reaching $3.02 billion. The company achieved a net income of $72 million for the year, a notable recovery from a loss in the previous year. Looking ahead, Amneal anticipates further growth in 2026 with projected revenues between $3.05 and $3.15 billion.
Read more →AMRXAmneal Pharmaceuticals Added to S&P SmallCap 600® Index
Amneal Pharmaceuticals has been added to the S&P SmallCap 600 Index, effective January 30, 2026. This inclusion highlights the company's consistent financial performance and operational strategy. The S&P SmallCap 600 is a key benchmark for small-cap stocks, and Amneal's addition is expected to increase its visibility and attract more investors.
Read more →AMRXAmneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
Amneal Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on February 27, 2026. The announcement will occur prior to market opening, followed by an audio webcast at 8:30 a.m. ET. Investors can access the results and the live webcast through the company's Investor Relations section on its website.
Read more →AMRXAmneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia and XGEVA
Amneal Pharmaceuticals has received FDA approval for two denosumab biosimilars, Boncresa™ and Oziltus™, expanding its biosimilar portfolio to five products. The company is aiming to commercialize six biosimilars across eight presentations by 2027, reinforcing its growth strategy in the Affordable Medicines segment. The partnership with mAbxience underlines a commitment to providing affordable biologics while maintaining high quality standards. Despite the positive news, the drugs come with specific warnings and potential side effects that necessitate careful administration and monitoring.
Read more →AMRXAmneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals
Amneal Pharmaceuticals has received FDA approval for its epinephrine injection in both single- and multi-dose vials, aimed at enhancing its injectables portfolio. This medication is crucial for emergency treatments in hospitals and acute care settings, addressing allergic reactions and severe hypotension. The approval reinforces Amneal's commitment to providing essential medicines, especially given the notable annual sales of approximately $118 million for this product. The introduction of both vial presentations is expected to improve access for healthcare providers across the U.S.
Read more →AMRXAmneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT for Parkinson’s Disease
Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study for CREXONT, an extended-release formulation of carbidopa and levodopa. The study indicated significant improvements in 'Good On' time for patients with Parkinson's disease compared to existing treatments, alongside notable reductions in 'Off' time and enhanced motor symptom control. While the interim findings highlight CREXONT's potential as an important therapeutic advancement, longer-term data and patient-reported outcomes are expected in 2026 to further establish its efficacy and safety.
Read more →AMRXAmneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol
Amneal Pharmaceuticals has received FDA approval for its albuterol sulfate inhalation aerosol, a generic version of PROAIR® HFA. This approval follows another recent FDA approval for beclomethasone dipropionate inhalation aerosol, marking significant progress in Amneal's respiratory drug offerings. The albuterol product is aimed at treating bronchospasm in patients aged 12 and older.
Read more →AMRXAmneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%
Amneal Pharmaceuticals has received FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a generic equivalent of RESTASIS. This product is designed to increase tear production in patients with dry eye syndrome. The approval highlights Amneal's capabilities in complex formulations and its commitment to addressing the needs of patients suffering from dry eye disease.
Read more →AMRXAmneal to Participate in Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. has announced participation in upcoming investor conferences, including the Piper Sandler 2025 Healthcare Conference and the J.P. Morgan 2026 Healthcare Conference. Executives Chirag Patel and Tasos Konidaris will represent the company, providing opportunities for direct engagement with the investment community. Webcasts of presentations will be available on Amneal's Investor Relations website.
Read more →AMRXAmneal Receives U.S. FDA Approval for Iohexol Injection
Amneal Pharmaceuticals, Inc. announced that the U.S. FDA has approved its iohexol injection, the first generic version of GE Healthcare's Omnipaque. This product, which is used for various imaging procedures in both adults and children, is anticipated to launch in the first quarter of 2026. The approval is a significant milestone for Amneal, reflecting its commitment to offering high-quality, affordable medicines and strengthening its position in the complex injectables market. However, the product carries notable safety warnings associated with its use.
Read more →AMRXAmneal Reports Third Quarter 2025 Financial Results
Amneal Pharmaceuticals reported a net revenue of $785 million for Q3 2025, reflecting a 12% increase from the previous year. The company achieved a net income of $2 million, marking a recovery from a loss in Q3 2024. Amneal's Specialty segment continues to grow, driven by key products like CREXONT® and the recent launch of BREKIYA®. The company also updated its 2025 guidance, indicating a positive outlook.
Read more →AMRXAmneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
Amneal Pharmaceuticals has received tentative approval from the FDA for its beclomethasone dipropionate HFA inhalation aerosol, a generic version of QVAR. This marks Amneal's first metered-dose inhaler product, expanding its presence in the respiratory therapy market. The inhaler is indicated for asthma maintenance treatment but not for acute bronchospasm relief. The product has a potential market value of approximately $329 million annually.
Read more →AMRXAmneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
Amneal Pharmaceuticals has launched Brekiya, the first ready-to-use dihydroergotamine autoinjector for treating migraines and cluster headaches in adults. Available by prescription through select pharmacies, Brekiya offers a convenient self-administration option, potentially reducing emergency room visits. This launch addresses the limited treatment options for those suffering from these debilitating conditions.
Read more →AMRXAmneal to Report Third Quarter 2025 Results on October 30, 2025
Amneal Pharmaceuticals, Inc. will release its third quarter 2025 financial results on October 30, 2025, before market opening. An audio webcast is scheduled for 8:30 a.m. ET, providing investors with access to the results and a conference call. The company continues to expand its diverse pharmaceutical portfolio.
Read more →AMRXAmneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
Amneal Pharmaceuticals has submitted a Biologics License Application (BLA) for a proposed biosimilar to XOLAIR (omalizumab) to the FDA. This submission is seen as a significant growth opportunity for Amneal, which plans to launch multiple biosimilars in the coming years. The company expects to incur a $22.5 million R&D milestone charge due to the earlier filing. Omalizumab is indicated for several severe allergic conditions but carries a risk of anaphylaxis.
Read more →AMRXAmneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Amneal Pharmaceuticals has received FDA approval for its bimatoprost ophthalmic solution 0.01%, a generic equivalent of LUMIGAN. This product is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The approval is part of Amneal's strategy to enhance its Affordable Medicines portfolio, addressing the increasing demand for effective glaucoma treatments.
Read more →AMRXAmneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
Amneal Pharmaceuticals has received FDA approval for its sodium oxybate oral solution, a treatment for narcolepsy. This approval allows Amneal to offer a more affordable option in a market previously dominated by a single manufacturer. Sodium oxybate is crucial for managing symptoms like excessive daytime sleepiness and cataplexy in patients aged 7 and older.
Read more →AMRXAmneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
Amneal Pharmaceuticals has received FDA approval for its risperidone extended-release injectable suspension, available in multiple dosages. This product is designed for treating schizophrenia and Bipolar I disorder, and is set to launch in Q4 2025. The approval marks a significant addition to Amneal's complex injectables portfolio, highlighting the company's manufacturing capabilities.
Read more →AMRXAMNEAL REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Q2 2025 Net Revenue of $725 million GAAP Net Income of $22 million Diluted Income per Share of $0.07 Adjusted EBITDA of $184 million Adjusted Diluted EPS of $0.25 Rais
Amneal Pharmaceuticals reported a strong second quarter for 2025, with a net revenue of $725 million and a net income of $22 million. The company noted a solid rise in revenue, particularly from its specialty products, alongside an increase in adjusted EBITDA. Amneal also successfully raised its full-year financial guidance and completed a debt refinancing that improved its capital structure. The quarter was marked by positive developments, including the FDA's approval of a new migraine treatment.
Read more →AMRXAmneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
Amneal Pharmaceuticals announced plans to refinance existing credit agreements through a $1.8 billion term loan and a $750 million offering of senior secured notes due 2032. The proceeds will be used to pay off current loans and related expenses. However, the transactions depend on market conditions, and there is uncertainty regarding their completion.
Read more →AMRXAmneal Reports Certain Preliminary Second Quarter 2025 Financial Results
Amneal Pharmaceuticals reported preliminary financial results for Q2 2025, indicating financial growth with net revenue expected between $720 million and $730 million, a 3% increase from the previous year. Additionally, income before income taxes is projected at $45 million to $56 million, significantly higher than the prior year's $20 million. The company also noted a decrease in gross and net leverage ratios, reflecting successful debt reduction. Furthermore, they highlight recent FDA approval for the Brekiya® autoinjector and anticipate a BLA submission for a proposed biosimilar to XOLAIR® later this year.
Read more →AMRXAmneal to Report Second Quarter 2025 Results on August 5, 2025
Amneal Pharmaceuticals, Inc. announced that it will release its financial results for the second quarter of 2025 on August 5, 2025, prior to market opening. An audio webcast to discuss these results will be hosted at 8:30 a.m. ET on the same day. The webcast and financial results will be available through the Investor Relations section of the Company's website. Registration for the webcast is encouraged, and a replay will be made available shortly after the live event.
Read more →AMRXAmneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
Amneal Pharmaceuticals announced positive topline results from a confirmatory clinical study for its biosimilar candidate ADL-018, a proposed alternative to XOLAIR (omalizumab). The study demonstrated equivalence in therapeutic efficacy and safety between ADL-018 and XOLAIR in treating patients with Chronic Idiopathic Urticaria. With an expected Biologics License Application (BLA) filing in Q4 2025, Amneal aims to leverage this opportunity in the lucrative U.S. market. The successful trial marks a significant advancement for both Amneal and Kashiv BioSciences in the biosimilars landscape.
Read more →AMRXAmneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Amneal Pharmaceuticals has received FDA approval for its prednisolone acetate ophthalmic suspension, a 1% sterile topical anti-inflammatory agent. The product is intended to treat steroid-responsive ocular inflammation and is set for commercial launch in Q3 2025. This approval highlights the company's robust R&D capabilities and is a significant addition to their Affordable Medicines portfolio, which aims to enhance access to high-quality treatments.
Read more →AMRXAmneal to Participate at Upcoming Investor Conferences in June
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) is set to participate in two important investor conferences in June 2025. The Jefferies Global Healthcare Conference will take place on June 5, followed by the Goldman Sachs Global Healthcare Conference on June 10. Co-CEO Chirag Patel and CFO Tasos Konidaris will represent the company, highlighting its commitment to investor relations. A live webcast of the presentations will be available for stakeholders.
Read more →AMRXAmneal Receives U.S. FDA Approval for Brekiya (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
Amneal Pharmaceuticals has received FDA approval for Brekiya, the first dihydroergotamine autoinjector, designed for the acute treatment of migraines and cluster headaches in adults. This innovative device allows patients to self-administer a familiar and effective medication previously only available in hospital settings. Brekiya offers a ready-to-use format that enhances convenience without the need for refrigeration or priming. The product is expected to be available to patients by the second half of 2025.
Read more →AMRXAmneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
Amneal Pharmaceuticals and Apiject Systems have announced a strategic collaboration to enhance U.S. pharmaceutical manufacturing by expanding Amneal's Brookhaven facility. This partnership will focus on producing sterile drug dosage forms, including prefilled injectables. The project is poised to create around 200 jobs and significantly increase production capacity, reinforcing the domestic pharmaceutical supply chain. The initiative follows government investment to enhance U.S. drug manufacturing capabilities.
Read more →AMRXAMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Q1 2025 Net Revenue of $695 million GAAP Net Income of $12 million Diluted Income per Share of $0.04 Adjusted EBITDA of $170 million Adjusted Diluted EPS of $0.21 Affir
Amneal Pharmaceuticals reported strong financial results for the first quarter of 2025, achieving net revenues of $695 million and a net income of $12 million. This marks a significant recovery from a net loss in the same quarter last year. The growth was attributed to the performance of its complex product portfolio and recent injectable products. The company also affirmed its full-year guidance for 2025, expecting revenues between $3.0 billion and $3.1 billion.
Read more →AMRXAMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Full Year 2024 Performance Met or Exceeded All Financial Guidance Metrics - Q4 2024 Net Revenue of $731 million GAAP Net Loss of $31 million Diluted Loss
Amneal Pharmaceuticals reported its financial results for the fourth quarter and full year 2024, highlighting that the performance met or exceeded all guidance metrics. The company reported Q4 net revenues of $731 million, an 18% increase from the previous year, though it faced a GAAP net loss of $31 million. For the full year, revenues reached $2.79 billion, up 17%, but the company also recorded a net loss of $117 million. Looking ahead, Amneal provided guidance for 2025, projecting revenues of $3.0 to $3.1 billion, signaling continued growth in high-potential areas such as Specialty and Biosimilars.
Read more →AMRXAMNEAL REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Q3 2024 Net Revenue of $702 million GAAP Net Loss of $0.2 million Diluted Loss per Share of $0.00 Adjusted EBITDA of $158 million Adjusted Diluted EPS of $0.16 Affirms
Amneal Pharmaceuticals reported its third quarter financial results for 2024, showing a net revenue of $702 million, which reflects a 13% increase from the previous year. Despite a GAAP net loss of $0.2 million, the company reported adjusted EBITDA growth of 2% to $158 million. The launch of CREXONT for Parkinson’s disease and a collaboration with Metsera are key strategic initiatives for future growth. Amneal also reaffirmed its full-year guidance, maintaining a positive outlook for 2024.
Read more →AMRXAmneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson's Disease to be launched as CREXONT (Carbidopa and Levodopa) Extended-Release Capsules Delivers more "Good On" time with less frequent dosing c ompa
Amneal Pharmaceuticals announced the U.S. FDA approval of CREXONT, an extended-release formulation of carbidopa and levodopa for treating Parkinson's disease. This innovative drug is designed to provide longer durations of 'Good On' time with fewer doses compared to existing immediate-release options. The launch is anticipated in September 2024, reflecting Amneal's commitment to serving the Parkinson's community. Despite the advantages, some side effects like nausea and anxiety may occur, emphasizing the need for careful patient management.
Read more →AMRX▲ +8.9%on this news
AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Q1 2024 Net Revenue of $659 million GAAP Net Loss of $92 million Diluted Loss per Share of $0.30 Adjusted EBITDA of $152 million Adjusted Diluted EPS of $0.14 Company h
Amneal Pharmaceuticals reported its financial results for the first quarter of 2024, highlighting a net revenue of $659 million, which is an 18% increase from the previous year. The company experienced growth across all of its business segments, with adjusted EBITDA rising to $152 million. However, the net loss rose to $92 million, partly due to a substantial charge related to an opioid settlement. Amneal retains its full year guidance for 2024, anticipating net revenue between $2.55 billion and $2.65 billion.
Read more →AMRXAMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics - Q4 2023 Net Revenue of $617 million GAAP Net Loss of $99 million Diluted Loss per
Amneal Pharmaceuticals reported its financial results for the fourth quarter and full year of 2023, showing increases in net revenue but also significant net losses. For Q4 2023, net revenue was $617 million, while the company faced a GAAP net loss of $99 million. The full year saw net revenue of $2.39 billion, representing an 8% rise from the previous year. Despite challenges in the generics segment, the company provided a positive 2024 financial outlook, anticipating further revenue growth and adjusted EBITDA improvements.
Read more →AMRXAmneal Announces Complete Response Resubmission for IPX203 New Drug Application
Amneal Pharmaceuticals has announced a Complete Response resubmission for its new drug application for IPX203, a novel oral formulation for treating Parkinson's disease. This follows an initial Complete Response Letter from the FDA, but the resubmission package, which includes data from a recent study, did not require additional trials. The company aims to launch the treatment in the second half of 2024, pending FDA approval. IPX203 is designed to enhance drug delivery and is distinct from Amneal’s previously approved product.
Read more →AMRX▲ +5.8%on this news
AMNEAL INVESTIGATION NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and Encourages Investors with Losses to Contact the Firm
Kaskela Law LLC has announced an investigation into Amneal Pharmaceuticals, Inc. (AMRX) on behalf of the company's shareholders. This investigation is triggered by a significant decline in the value of Amneal's stock, which has dropped from over $14.00 per share to under $6.00 in the past few years. The law firm is looking into whether the company or its representatives failed to comply with securities laws by making misleading statements and not disclosing critical information to investors. Shareholders are encouraged to reach out for more information regarding their potential legal options.
Read more →AMRXAmneal Announces Move to Nasdaq Nasdaq move will be effective on
Amneal Pharmaceuticals, Inc. announced its decision to move its stock listing from the New York Stock Exchange to the Nasdaq, effective December 27, 2023. The company will continue trading under the symbol AMRX and will be included in the Nasdaq Composite Index and Nasdaq Biotechnology Index. Executives expressed optimism about the move, citing increased visibility and potential for growth. Amneal is a diversified pharmaceutical company focused on essential medicines with a robust product pipeline.
Read more →AMRXAMNEAL REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Q3 2023 Net Revenue of $620 million GAAP Net Income of $10 million Diluted EPS of $0.06 Q3 2023 Adjusted Net Income (1) of $60 million Adjusted EBITDA (1) of $154 milli
Amneal Pharmaceuticals reported a strong third quarter for 2023, achieving a net revenue of $620 million, a 14% increase from the previous year. The company also noted a net income of $10 million, reflecting a recovery from a net loss in Q3 2022. Amneal has raised its full-year guidance, anticipating revenues between $2.37 billion to $2.42 billion, driven by the success of new product launches and robust growth across its business segments. The company remains focused on expanding its portfolio and delivering value to shareholders, with plans to launch more than 40 new generic products in 2023.
Read more →AMRX▲ +22.3%on this news· ran to +37% by day 1
AMNEAL REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Q2 2023 Net Revenue of $599 million GAAP Net Income of $12 million Diluted EPS of $0.08 Q2 2023 Adjusted Net Income (1) of $57 million Adjusted EBITDA (1) of $146 mill
Amneal Pharmaceuticals reported strong financial results for Q2 2023, with net revenue of $599 million, up 7% from Q2 2022. The company recorded a net income of $12 million, a substantial improvement from a net loss of $121 million in the prior year. Amneal has raised its full year guidance, expecting net revenue to reach between $2.30 and $2.40 billion. The increase in revenue is attributed to growth in generics, biosimilars, and an expanding product portfolio.
Read more →AMRXIN THE COURT OF CHANCERY OF THE STATE OF DELAWARE RUSSELL THIELE and JEFFREY ) EDELMAN, Derivatively on Behalf of ) AMNEAL PHARMACEUTICALS, ) INC., ) Plaintiffs, ) ) v. ) C.A. No. 2022-0272-LWW ) KASHIV BIOSCIENCES, LLC,
A proposed settlement has been reached for a derivative lawsuit concerning Amneal Pharmaceuticals and its acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals. The settlement aims to confer various benefits to Amneal, though direct financial compensation will not be provided to individual stockholders. A hearing is scheduled to evaluate the fairness of the settlement and to possibly approve the agreement. The action was originally taken by current stockholders alleging breach of fiduciary duty related to the acquisition.
Read more →AMRXAMNEAL REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Q1 2023 Net Revenue of $558 million GAAP Net Loss of $7 million Diluted Loss per Share of $0.05 Adjusted EBITDA (1) of $116 million Adjusted Diluted EPS (1) of $0.12 Af
Amneal Pharmaceuticals reported its Q1 2023 financial results, showing a 12% rise in net revenue to $558 million, yet a net loss of $7 million. Adjusted EBITDA grew 16% from the previous year, reflecting robust performance in its generics and specialty portfolios. The company affirmed its full-year guidance with expectations of $2.25 billion to $2.35 billion in net revenue. Additionally, Amneal announced the successful inspection of its largest injectables facility and is preparing for a key PDUFA date for a Parkinson's treatment.
Read more →AMRXAMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Q4 2022 Net Revenue of $610 million GAAP Net Loss of $4 million Diluted Loss per Share of $0.03 Q4 2022 Adjusted Net Income of $71 million (1) , Adjusted
Amneal Pharmaceuticals reported its financial results for Q4 and full year 2022, highlighting a 14% increase in Q4 net revenue to $610 million. Despite the revenue growth, the company faced a GAAP net loss of $130 million for the full year, largely due to a significant legal settlement. Looking ahead, Amneal provided financial guidance for 2023, forecasting continued revenue growth between $2.25 and $2.35 billion and improved adjusted EBITDA. The company aims to leverage its strategic initiatives in generics and biosimilars to drive performance in the coming year.
Read more →AMRXAMNEAL REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Q3 2022 Net Revenue of $546 million GAAP Net Loss of $3 million Diluted Loss per Share of $(0.02) Adjusted EBITDA (1) of $126 million Adjusted Diluted EPS (1) of $0.14
AMNEAL REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Q3 2022 Net Revenue of $546 million GAAP Net Loss of $3 million Diluted Loss per Share of $(0.02) Adjusted EBITDA (1) of $126 million Adjusted Diluted EPS (1) of $0.14 Maintaining 2022 Full Year Outlook BRIDGEWATER, NJ, Nove
Read more →AMRXAmneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer Specialty
Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer Specialty BRIDGEWATER, N.J. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ( Amneal or the Company ) today announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial O
Read more →AMRX▼ -8.1%on this news
AMNEAL REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Q2 2022 Net Revenue of $559 million GAAP Net Loss of $121 million Diluted Loss per Share of $(0.80) Adjusted EBITDA (1) of $135 million Adjusted Diluted EPS (1) of $0.
AMNEAL REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Q2 2022 Net Revenue of $559 million GAAP Net Loss of $121 million Diluted Loss per Share of $(0.80) Adjusted EBITDA (1) of $135 million Adjusted Diluted EPS (1) of $0.19 Updates 2022 Adjusted EBITDA guidance BRIDGEWATER, NJ
Read more →AMRXAmneal Appoints Deborah M. Autor to Board of Directors - Adds new independent director with deep biopharmaceutical industry expertise in quality, regulatory and policy
Amneal Appoints Deborah M. Autor to Board of Directors - Adds new independent director with deep biopharmaceutical industry expertise in quality, regulatory and policy BRIDGEWATER, N.J. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ( Amneal or the Company ) today announced that De
Read more →AMRX▼ -7%on this news· ran to -22% by day 3
AMNEAL REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Q1 2022 Net Revenue of $498 million GAAP Net Loss of $2 million Diluted Loss per Share of $(0.01) Adjusted EBITDA (1) of $100 million includes $5 million of R D milesto
AMNEAL REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Q1 2022 Net Revenue of $498 million GAAP Net Loss of $2 million Diluted Loss per Share of $(0.01) Adjusted EBITDA (1) of $100 million includes $5 million of R D milestone expense Adjusted Diluted EPS (1) of $0.12 Maintaining
Read more →AMRX▼ -9.7%on this news
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS Q4 2021 Net Revenue of $537 million GAAP Net Loss of $6 million Diluted Loss per Share of $0.04 Q4 2021 Adjusted Net Income of $54 million (1) , Adjusted
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS Q4 2021 Net Revenue of $537 million GAAP Net Loss of $6 million Diluted Loss per Share of $0.04 Q4 2021 Adjusted Net Income of $54 million (1), Adjusted EBITDA (1) of $126 million Adjusted Diluted EPS (1) of $0.
Read more →AMRXAmneal Acquires Saol Therapeutics Baclofen Franchise - Expands Amneal s Neurology Presence into Spasticity
Amneal Acquires Saol Therapeutics Baclofen Franchise - Expands Amneal s Neurology Presence into Spasticity BRIDGEWATER, N.J. and ROSWELL, GA (BUSINESSWIRE) Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ( Amneal ) and Saol Therapeutics, a private specialty pharmaceutical company (
Read more →AMRX▼ -8.6%on this news
AMNEAL REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS Q3 2021 Net Revenue of $529 million GAAP Net Loss of $(4) million Diluted Loss per Share of $(0.03) Adjusted EBITDA (1) of $135 million Adjusted Diluted EPS (1) of $0.2
AMNEAL REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS Q3 2021 Net Revenue of $529 million GAAP Net Loss of $(4) million Diluted Loss per Share of $(0.03) Adjusted EBITDA (1) of $135 million Adjusted Diluted EPS (1) of $0.21 Updating 2021 Full Year Financial Outlook, Including Ra
Read more →AMRX▲ +5.5%on this news
AMNEAL REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS Q2 2021 Net Revenue of $535 million GAAP Net Income of $15 million Diluted Income per Share of $0.10 Adjusted EBITDA (1) of $151 million Adjusted Diluted EPS (1) of $0
AMNEAL REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS Q2 2021 Net Revenue of $535 million GAAP Net Income of $15 million Diluted Income per Share of $0.10 Adjusted EBITDA (1) of $151 million Adjusted Diluted EPS (1) of $0.25 Maintaining 2021 Full Year Financial Outlook BRIDGEW
Read more →AMRXAMNEAL REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS Q1 2021 Net Revenue of $493 million GAAP Net Income of $7 million Diluted Income per Share of $0.04 Adjusted EBITDA (1) of $126 million Adjusted Diluted EPS (1) of $0.2
AMNEAL REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS Q1 2021 Net Revenue of $493 million GAAP Net Income of $7 million Diluted Income per Share of $0.04 Adjusted EBITDA (1) of $126 million Adjusted Diluted EPS (1) of $0.20 Maintaining 2021 Full Year Financial Outlook BRIDGEWAT
Read more →AMRXAmneal Completes Acquisition of Kashiv Specialty Pharmaceuticals Bridgewater, New Jersey
Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals Bridgewater, New Jersey April 5, 2021 Amneal Pharmaceuticals, Inc. (the Company ) (NYSE: AMRX) and Kashiv BioSciences LLC ( Kashiv ) today announced that Amneal Pharmaceuticals LLC ( Amneal ), a subsidiary of the
Read more →AMRXAMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Q4 2020 Net Revenue of $510 million GAAP Net Loss of $3 million Diluted Loss per Share of $0.02 Q4 2020 Adjusted Net Income (1) of $43 million Adjusted E
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS Q4 2020 Net Revenue of $510 million GAAP Net Loss of $3 million Diluted Loss per Share of $0.02 Q4 2020 Adjusted Net Income (1) of $43 million Adjusted EBITDA (1) of $107 million Adjusted Diluted EPS (1) of $0.1
Read more →AMRXAmneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals Bridgewater, New Jersey
Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals Bridgewater, New Jersey January 11, 2021 Amneal Pharmaceuticals, Inc. (the Company ) (NYSE: AMRX) and Kashiv BioSciences LLC ( Kashiv ) today announced they have entered into a definitive agreement under wh
Read more →AMRXAMNEAL REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS Q3 2020 Net Revenue of $519 million GAAP Net Loss of $(9) million Diluted Loss per Share of $(0.06) Q3 2020 Adjusted Net Income (1) of $49 million Adjusted EBITDA (1) o
AMNEAL REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS Q3 2020 Net Revenue of $519 million GAAP Net Loss of $(9) million Diluted Loss per Share of $(0.06) Q3 2020 Adjusted Net Income (1) of $49 million Adjusted EBITDA (1) of $114 million Adjusted Diluted EPS (1) of $0.16 Updating
Read more →AMRXAMNEAL REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Q2 2020 Net Revenue of $465 million GAAP Net Loss of $(12) million Diluted Loss per Share of $(0.08) Q2 2020 Adjusted Net Income (1) of $38 million Adjusted EBITDA (1)
AMNEAL REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS Q2 2020 Net Revenue of $465 million GAAP Net Loss of $(12) million Diluted Loss per Share of $(0.08) Q2 2020 Adjusted Net Income (1) of $38 million Adjusted EBITDA (1) of $101 million Adjusted Diluted EPS (1) of $0.13 Mainta
Read more →AMRXAMNEAL REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Q1 2020 Net Revenue of $ 499 million; GAAP Net Income of $115 million; Diluted Earnings per Share of $0.78 Q1 2020 Adjusted Net Income (1) of $60 million; Adjusted EBIT
AMNEAL REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS Q1 2020 Net Revenue of $ 499 million; GAAP Net Income of $115 million; Diluted Earnings per Share of $0.78 Q1 2020 Adjusted Net Income (1) of $60 million; Adjusted EBITDA (1) of $134 million; Adjusted Diluted EPS (1) of $0.20
Read more →AMRXAmneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer
Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer BRIDGEWATER, N.J. (BUSINESS WIRE) Amneal Pharmaceuticals, Inc. (NYSE: AMRX) ( Amneal or the Company ) today announced it has appointed Tasos Konidaris as Senior Vice President, Chi
Read more →AMRXTodd Branning (908) 280-6019 AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS Q4 2019 Net Revenue of $397 million; GAAP Loss per share of ($0.23); Net Loss of ($32 million) Q4 2019 Adjusted EBI
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS Q4 2019 Net Revenue of $397 million; GAAP Loss per share of ($0.23); Net Loss of ($32 million) Q4 2019 Adjusted EBITDA(1) of $81 million; Adjusted Diluted EPS (1) of $0.08 Full Year Net Revenue of $1.63 billion
Read more →AMRXAmneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors Three Independent Directors Bring Significant Pharmaceutical, Healthcare and Financial Expertise and Track Records of Creating Value for Shar
Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors Three Independent Directors Bring Significant Pharmaceutical, Healthcare and Financial Expertise and Track Records of Creating Value for Shareholders BRIDGEWATER, N.J. December 16, 2019 Amneal Pharm
Read more →AMRXAmneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market Bridgewater, New Jersey and Fountain Run, Kentucky
Amneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market Bridgewater, New Jersey and Fountain Run, Kentucky December 10, 2019 Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and AvKARE Inc. today announced they have entered into a definiti
Read more →AMRXMark Donohue (908) 409-6718 AMNEAL REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Q3 2019 Net Revenue of $378 million; GAAP Loss per share of ($2.03); Adjusted Diluted EPS (1) of $0.04 Positive Cash Flow from Oper
AMNEAL REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS Q3 2019 Net Revenue of $378 million; GAAP Loss per share of ($2.03); Adjusted Diluted EPS (1) of $0.04 Positive Cash Flow from Operations of $140 million Executing on Near-Term Strategic Actions to Accelerate Business Perform
Read more →AMRXThe reader is cautioned not to rely on these forward-looking statements.
AMNEAL REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS Q2 2019 Net Revenue of $405 Million; GAAP Loss per share of $0.13; Combined Adjusted Diluted EPS(1) of $0.09 Positive cash flow from operations of $21 million Reaffirms Full Year 2019 EBITDA Guidance Investor Call at 8:30 a
Read more →AMRXTargeting up to 50 New Generic Product Launches in 2019
AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS Q4 2018 Net Revenue of $498 Million; GAAP Loss per share of $0.07; Combined Adjusted Diluted EPS(1) of $0.33 Full Year 2018 Net Revenue of $1.66 Billion; GAAP Loss per share of $0.16; Combined Net Revenue(1)of $
Read more →AMRXDATED JANUARY 4, 2019 Exhibit CONTACT: Mark Donohue (908) 409-6718 AMNEAL NAMES DAVID A. BUCHEN SENIOR VICE PRESIDENT
CONTACT: Mark Donohue (908) 409-6718 AMNEAL NAMES DAVID A. BUCHEN SENIOR VICE PRESIDENT, CHIEF LEGAL OFFICER AND CORPORATE SECRETARY BRIDGEWATER, N.J., January 4, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that it has appointed David A. Buc
Read more →AMRXIntegration of Amneal and Impax Nearing Completion; On Track to Achieve More Than $200 Million in Cost Synergies
AMNEAL ANNOUNCES SOLID THIRD QUARTER 2018 FINANCIAL RESULTS Net Revenue of $476 Million; Diluted EPS of $0.05; Adjusted Diluted EPS of $0.28 Integration of Amneal and Impax Nearing Completion; On Track to Achieve More Than $200 Million in Cost Synergies Company Tightens Existi
Read more →AMRXIntegration of Amneal and Impax Advancing Ahead of Schedule; On Track to Achieve More Than $200 Million in Cost Synergies
AMNEAL ANNOUNCES SOLID SECOND QUARTER 2018 FINANCIAL RESULTS GAAP Net Revenue of $414 Million; Adjusted Net Revenue of $462 Million on a Combined Company Basis GAAP Loss Per Diluted Share of $0.15; Adjusted Income Per Share of $0.24 on a Combined Company Basis Integration of A
Read more →AMRXImpax Laboratories, LLC Announces Results Of Tender Offer for 2.00% Convertible Senior Notes Due 2022
Impax Laboratories, LLC Announces Results Of Tender Offer for 2.00% Convertible Senior Notes Due 2022 HAYWARD, Cal., June 5, 2018 /PRNewswire/ Impax Laboratories, LLC ( Impax or the Company ), a wholly-owned subsidiary of Amneal Pharmaceuticals, Inc. (NYSE: AMRX), announced tod
Read more →AMRXWe make healthy possible" UBS Global Healthcare Conference Focused on Rob Stewart Growth & President and CEO Execution
"We make healthy possible" UBS Global Healthcare Conference Focused on Rob Stewart Growth & President and CEO Execution May 21, 2018 A Strong Foundation to Deliver Long-Term Growth GENERIC PRODUCT SPECIALTY PRODUCTS OUR PORTFOLIO FOCUS R&D CENTERS GLOBAL MANUFACTURING FAMILIES F
Read more →AMRXMark Donohue (215) 558-4526 AMNEAL AND IMPAX COMPLETE BUSINESS COMBINATION Creates Diversified Pharmaceutical Company with 5th Largest Generics Business in the United States Combined First
AMNEAL AND IMPAX COMPLETE BUSINESS COMBINATION Creates Diversified Pharmaceutical Company with 5th Largest Generics Business in the United States Combined First Quarter 2018 Total Revenues of $418 Million; GAAP Net Loss of $79 million; Adjusted EBITDA of $96 Million Provides F
Read more →AMRXAmneal Pharmaceuticals Selects StayinFront Mobile Cloud CRM Solution
SYDNEY, AUSTRALIA--(Marketwired - February 16, 2016) - StayinFront, a global leader of mobile SaaS customer relationship management (CRM) solutions, announced today that Amneal Pharmaceuticals, a leading global generics manufacturer, will deploy StayinFront on-demand CRM and ana
Read more →Competitive Position
How AMRX ranks across every disease it competes inCompetitive Position is a premium feature
See how AMRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial